P7‐13: Identification of exacerbation phenotypes across asthma and COPD

OE), SIRT3 knockout (SIRT3 KO) male mice. The next day (early phase) and 4weeks later (late phase) after LPS administration, BALF analysis and lung function test were conducted. Then, we examined the effect of SIRT3 on LPS-induced cytokine production, using BEAS-2B cells. Results: In early phase, the BALF cell count of SIRT3 OE mice was significantly increased compared to control WT mice, whereas that of SIRT3 KO mice was significantly decreased. In late phase, the lung compliance was increased in SIRT3 OE mice compared to WT mice, and decreased in SIRT3 KO mice. In vitro studies, SIRT3 transfection suppressed the LPSinduced expressions of IL-8 and G-CSF. Conclusions: Our study showed that SIRT3 suppressed acute lung injury and emphysematous worsening in COPD model mice and airway epithelial cells. SIRT3 would serve as a new therapeutic target to COPD and COPD exacerbation.